BRCA-deficient mouse mammary tumor organoids to study cancer-drug resistance

Poly(ADP-ribose) polymerase inhibition (PARPi) is a promising new therapeutic approach for the treatment of cancers that show homologous recombination deficiency (HRD). Despite the success of PARPi in targeting HRD in tumors that lack the tumor suppressor function of BRCA1 or BRCA2, drug resistance...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nature methods Jg. 15; H. 2; S. 134
Hauptverfasser:	Duarte, Alexandra A, Gogola, Ewa, Sachs, Norman, Barazas, Marco, Annunziato, Stefano, R de Ruiter, Julian, Velds, Arno, Blatter, Sohvi, Houthuijzen, Julia M, van de Ven, Marieke, Clevers, Hans, Borst, Piet, Jonkers, Jos, Rottenberg, Sven
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States Nature Publishing Group 01.02.2018
Schlagworte:	Adenosine diphosphate Animal models Animals Antineoplastic Agents - pharmacology ATP Binding Cassette Transporter, Subfamily B - physiology BRCA1 Protein BRCA2 protein BRCA2 Protein - deficiency Breast cancer Cancer Cell Proliferation - drug effects Drug resistance Drug Resistance, Neoplasm Female Genetic engineering Genetic modification Homologous recombination Homology Mammary gland Mammary Neoplasms, Animal - drug therapy Mammary Neoplasms, Animal - metabolism Mammary Neoplasms, Animal - pathology Mice Mice, Knockout Organ Culture Techniques Organoids Organoids - drug effects Organoids - metabolism Organoids - pathology Poly(ADP-ribose) Poly(ADP-ribose) polymerase Poly(ADP-ribose) Polymerase Inhibitors - pharmacology Ribose Three dimensional models Tumor suppressor genes Tumor Suppressor Proteins - deficiency Tumors
ISSN:	1548-7091, 1548-7105, 1548-7105
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!